FOXFIRE protocol: An open-label, randomised, phase III trial of 5-fluorouracil, oxaliplatin and folinic acid (OxMdG) with or without interventional Selective Internal Radiation Therapy (SIRT) as first-line treatment for patients with unresectable liver-only or liver-dominant metastatic colorectal cancer

BMC Cancer

Volumn 14, Issue 1, 2014, Pages

  Dutton, Susan J ^a   Kenealy, Nicola ^b   Love, Sharon B ^a   Wasan, Harpreet S ^c   Sharma, Ricky A ^a  

^a UNIVERSITY OF OXFORD   (United Kingdom)

^b UNIVERSITY OF OXFORD   (United Kingdom)

^c HAMMERSMITH HOSPITAL   (United Kingdom)

Author keywords

Brachytherapy; Colorectal cancer; Health economics; Liver metastases; Quality of life; Radio embolization; Radiosensitisation; Radiosensitization; Selective Internal Radiation Therapy (SIRT)

Indexed keywords

FLUOROURACIL; FOLINIC ACID; OXALIPLATIN; ANTINEOPLASTIC AGENT; PLATINUM COMPLEX; RADIOSENSITIZING AGENT; YTTRIUM;

ADULT; ARTICLE; CANCER RADIOTHERAPY; CANCER SURVIVAL; CLINICAL EFFECTIVENESS; CLINICAL PROTOCOL; COLORECTAL CARCINOMA; COMPUTER ASSISTED TOMOGRAPHY; CONTINUOUS INFUSION; CONTROLLED STUDY; DISEASE ASSOCIATION; DRUG DOSE REDUCTION; DRUG EFFICACY; HISTOPATHOLOGY; HUMAN; INOPERABLE CANCER; INTERVENTIONAL RADIOLOGY; LIFE EXPECTANCY; LIVER METASTASIS; LUNG NODULE; METASTATIC COLORECTAL CANCER; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PATIENT SAFETY; PHASE 3 CLINICAL TRIAL; PROGRESSION FREE SURVIVAL; RANDOMIZATION; RANDOMIZED CONTROLLED TRIAL; SELECTIVE INTERNAL RADIATION THERAPY; SURVIVAL TIME; TREATMENT CONTRAINDICATION; TUMOR VOLUME; CLINICAL TRIAL; COLORECTAL NEOPLASMS; DISEASE FREE SURVIVAL; LIVER NEOPLASMS; MULTIMODALITY CANCER THERAPY; PROCEDURES; SECONDARY;

ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; COLORECTAL NEOPLASMS; COMBINED MODALITY THERAPY; DISEASE-FREE SURVIVAL; FLUOROURACIL; HUMANS; LEUCOVORIN; LIVER NEOPLASMS; ORGANOPLATINUM COMPOUNDS; RADIATION-SENSITIZING AGENTS; RADIOTHERAPY; YTTRIUM RADIOISOTOPES;

EID: 84903856363     PISSN: None     EISSN: 14712407     Source Type: Journal    
DOI: 10.1186/1471-2407-14-497     Document Type: Article

References (14)

1. SEER Stat Fact Sheets Colon and Rectum Cancer, 2003-2009. [http://www.seer.cancer.gov/statfacts/html/colorect.html], SEER Stat Fact Sheets.
2. Peeters M, Price T. Biologic therapies in the metastatic colorectal cancer treatment continuum-applying current evidence to clinical practice. Cancer Treat Rev 2012, 38(5):397-406.
3. Abbas S, Lam V, Hollands M. Ten-year survival after liver resection for colorectal metastases: systematic review and meta-analysis. ISRN Oncol 2011, 2011:763245.
4. Fong Y, Fortner J, Sun RL, Brennan MF, Blumgart LH. Clinical score for predicting recurrence after hepatic resection for metastatic colorectal cancer: analysis of 1001 consecutive cases. Ann Surg 1999, 230(3):309-318. discussion 318-321.
5. Choti MA, Sitzmann JV, Tiburi MF, Sumetchotimetha W, Rangsin R, Schulick RD, Lillemoe KD, Yeo CJ, Cameron JL. Trends in long-term survival following liver resection for hepatic colorectal metastases. Ann Surg 2002, 235(6):759-766.
6. Nordlinger B, Van Cutsem E, Gruenberger T, Glimelius B, Poston G, Rougier P, Sobrero A, Ychou M, . European Colorectal Metastases Treatment Group; Sixth International Colorectal Liver Metastases Workshop Does chemotherapy prior to liver resection increase the potential for cure in patients with metastatic colorectal cancer? A report from the European Colorectal Metastases Treatment Group. Eur J Cancer 2007, 43(14):2037-2045. European Colorectal Metastases Treatment Group; Sixth International Colorectal Liver Metastases Workshop.
7. Nicolay NH, Berry DP, Sharma RA. Liver metastases from colorectal cancer: radioembolization with systemic therapy. Nat Rev Clin Oncol 2009, 6(12):687-697.
8. Wang LM, Jani AR, Hill EJ, Sharma RA. Anatomical basis and histopathological changes resulting from selective internal radiotherapy for liver metastases. J Clin Pathol 2013, 66:205-211.
9. Gray B, Van Hazel G, Hope M, Burton M, Moroz P, Anderson J, Gebski V. Randomised trial of SIR-Spheres plus chemotherapy vs. chemotherapy alone for treating patients with liver metastases from primary large bowel cancer. Ann Oncol 2001, 12(12):1711-1720.
10. Van Hazel G, Blackwell A, Anderson J, Price D, Moroz P, Bower G, Cardaci G, Gray B. Randomised phase 2 trial of SIR-Spheres plus fluorouracil/leucovorin chemotherapy versus fluorouracil/leucovorin chemotherapy alone in advanced colorectal cancer. J Surg Oncol 2004, 88(2):78-85.
11. Sharma RA, Van Hazel GA, Morgan B, Berry DP, Blanshard K, Price D, Bower G, Shannon JA, Gibbs P, Steward WP. Radioembolization of liver metastases from colorectal cancer using yttrium-90 microspheres with concomitant systemic oxaliplatin, fluorouracil, and leucovorin chemotherapy. J Clin Oncol 2007, 25(9):1099-1106.
12. Brown S, Thorpe H, Hawkins K, Brown J. Minimization - reducing predictability for multi-centre trials whilst retaining balance within centre. Stat Med 2005, 24(24):3715-3727.
13. Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, Dancey J, Arbuck S, Gwyther S, Mooney M, Rubinstein L, Shankar L, Dodd L, Kaplan R, Lacombe D, Verweij J. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 2009, 45(2):228-247.
14. NHS England announces hospitals chosen to take part in new initiative aimed at increasing access to radiotherapy. http://www.england.nhs.uk/2013/11/20/sirt-comm.